circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X 31st Annual Piper Jaffray Healthcare Conference
    Dec 4, 2019 1:00 PM EST

    31st Annual Piper Jaffray Healthcare Conference
    Dec 4, 2019 1:00 PM EST
  • Webcast
    X Q3 2019 Cytokinetics, Inc. Earnings Conference Call
    Oct 31, 2019 4:30 PM EDT

    Q3 2019 Cytokinetics, Inc. Earnings Conference Call
    Oct 31, 2019 4:30 PM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND
Subgroup Analyses of FORTITUDE-ALS on Effects of Reldesemtiv with and without Concomitant Radicava® (edaravone) or Rilutek® (riluzole) SOUTH SAN FRANCISCO, Calif. , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new results were presented at the 30
Toggle Summary Cytokinetics to Participate in the Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research & Development, is scheduled to participate in a fireside chat at the 31 st Annual Piper Jaffray Healthcare
Toggle Summary Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five poster presentations at the 30 th International Symposium on ALS/MND in Perth, Australia . The posters will be presented on Thursday, December 5, 2019 and Friday, December
Toggle Summary New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function
THOUSAND OAKS, Calif. , SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, Nov. 18, 2019 /PRNewswire/ --  Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier announced that new results from COSMIC-HF ( C hronic  O ral  S tudy of  M yosin Activation to  I ncrease  C

EVENTS

There are currently no events to display.